<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413813</url>
  </required_header>
  <id_info>
    <org_study_id>MAGMARIS-ES</org_study_id>
    <nct_id>NCT03413813</nct_id>
  </id_info>
  <brief_title>Registry of Patients With a Bioabsorbable Magnesium Stent Implant MAGMARIS in Usual Clinical Practice</brief_title>
  <acronym>MAGMARIS</acronym>
  <official_title>Prospective Observational Registry of Patients With a Bioabsorbable Magnesium Stent Implant -MAGMARIS- in Usual Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Society of Cardiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and efficacy of percutaneous coronary revascularization has been progressively
      increasing since its inception, and the problem of restenosis has been minimized.

      The efficacy and safety data of the Magmaris stent are quite high, in selected cases.

      The objective is to evaluate the efficacy and safety of the bioabsorbable stent MAGMARIS in
      the percutaneous treatment of severe coronary disease (in vessels between 2.7mm and 3.75 mm)
      in routine clinical practice in poorly selected populations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, observational, prospective registry of patients without a control
      group designed to evaluate the efficacy and safety of the bioabsorbable coronary device,
      according to the indications for use, in routine clinical practice in a consecutive number of
      patients undergoing percutaneous coronary intervention (PCI) in de novo coronary arteries
      lesions in a native coronary artery.

      After the implantation of the device, a telephone or face-to-face follow-up will be carried
      out in the first month, at 12 months and at 24 months.

      A total of 1,235 patients are expected to be included in the registry. Patients, will be
      included consecutively in each center over a year. A selection period of 12 months or until
      the estimated sample size has been planned, with a follow-up of two years. Subsequently, it
      will take at least 3 months for data analysis, another 2 months for the final report and at
      least 3 more months for the publication of the results for publication. This implies that the
      total duration of the study will be 44 months counted from the inclusion of the first
      patient.

      The procedure will be carried out according to the usual practice of each center, paying
      special attention to the correct expansion of the scaffold, postdilating with non-compliant
      balloons when necessary.

      The collection of information from the study will be carried out on a data collection
      template in electronic format, which will include clinical, anatomical, procedural and
      follow-up data; in baseline circumstances, during hospitalization, after discharge and
      throughout follow-up at 1, 12, and 24 months. The source documents will be the patient's
      medical records collected at the center.

      The monitoring will be done monthly and online. Two face-to-face monitoring will be done to
      20% of the patients, during the inclusion and follow-up phases. Afterwards, a face-to-face
      monitoring will be carried out for the closing visit.

      Descriptive and univariate statistics will be performed. The primary variable is the MACE
      rate at 12 months, composed of cardiac death, myocardial infarction and TLR induced by
      ischemia (primary objectives). The secondary variables will be combined indices of events
      both in the hospital phase, and after discharge in the follow-up at 1, 12 and 24 months.

      A final report will be prepared containing all the results of the study, in a period of 6
      months once the same one finalized. The participating researchers and the Ethical Committees
      of the hospitals will be informed about this.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2017</start_date>
  <completion_date type="Anticipated">July 26, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 26, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>A combined rate (incidence of events) of:</measure>
    <time_frame>24 months</time_frame>
    <description>The cardiac death (incidence of events).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>A combined rate (incidence of events) of:</measure>
    <time_frame>24 months</time_frame>
    <description>Myocardial infarction (incidence of events)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>A combined rate (incidence of events) of:</measure>
    <time_frame>24 months</time_frame>
    <description>Revascularization of the treated lesion (TLR) induced by ischemia (incidence of events)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>Cardiovascular deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>Non-cardiovascular deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>Myocardial infarctions (MI: QMI and NQMI, TV, NTV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>Revascularization of the treated lesions induced by ischemia (ID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>Revascularization of the treated vessels induced by ischemia (ID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>All revascularizations (PCI vs. CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>Thrombosis of the device. Classification (acute, sub-acute, delayed) and evidence classification (definitive, probable, possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>Overlapping devices and features</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>The immediate success of the device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>The immediate success if the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>The failure of the lesion treated through a combined rate of cardiac death, TV-IM and ID-TLR: (Failure of treated lesion (TLF))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The event rate will be calculated for:</measure>
    <time_frame>24 months</time_frame>
    <description>The failure of the vessel treated through a combined rate of cardiac death, total myocardial infarction and ID-TVR: (Failure of treated vessel (TVF))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of:</measure>
    <time_frame>24 months</time_frame>
    <description>Overlapping stents will be calculated in relation to those implanted, and the relation with the appearance of clinical events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of:</measure>
    <time_frame>24 months</time_frame>
    <description>Image parameters will be calculated in the cases in which, in the opinion of the researcher, coronary function or intravascular imaging tests have been performed (FFR, IVUS, OCT).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1235</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magmaris</intervention_name>
    <description>Severe stenosis de novo, in native coronary arteries, treated with percutaneous coronary intervention with scaffold implantation.</description>
    <other_name>Bioresorbable scaffold</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ischemic heart disease by de novo lesions in native coronary arteries,
        candidates for revascularization with coronary stent.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BASIC CRITERIA:

               -  Patients who agree to participate in the study, signing the informed consent
                  form.

               -  The implantation of the bioresorbable MAGMARIS coronary device used according to
                  the indications for use in the center's routine clinical practice.

               -  Patients of both sexes over 18 years of age.

               -  The patient does not present any contraindication regarding the taking of dual
                  therapy of antiplatelet therapy with aspirin indefinitely and with
                  thienopyridines for at least the first 6 months.

          -  CLINICAL CRITERIA:

               -  Angor stable or anginal equivalent diagnosis of stable chronic ischemic heart
                  disease.

               -  Documented silent ischemia

               -  Acute coronary syndrome (excluding AMI with ST-segment elevation &lt;24 hours)

               -  Angina Equivalent

          -  ANGIOGRAPHICAL CRITERIA:

               -  One or more de novo lesions (stenosis&gt; 70% by visual estimation or&gt; 50% by
                  estimation of quantitative automatic angiography) in native coronary arteries.

               -  Vessel reference diameter ≥2.7 and ˂3.75.

               -  Maximum length of the lesion to be treated must be less than the nominal length
                  of the device (15 mm, 20 mm, 25 mm) or capable of being covered with more than
                  one scaffold implanted in an overlapped manner by at least 1 mm with respect to
                  the adjacent.

        Exclusion Criteria:

          -  CLINICS:

               -  Cardiogenic shock

               -  Acute Myocardial Infarction (first 24 hours).

               -  Concurrent diseases with life expectancy of less than 1 year

               -  Women of reproductive age who do not use contraception.

               -  Women who are pregnant or breast-feeding.

               -  Allergies: AAS, Thienopyridines, Magnesium.

          -  ANATOMICS:

               -  Main coronary artery lesion

               -  Lesion in aorto-coronary graft of saphenous vein or mammary artery.

               -  Intra-stent restenosis lesion.

               -  Lesion chronic total occlusion.

               -  Bifurcation lesion

               -  Severely calcified or severely tortuous coronary artery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres I Romo, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Spanish Society of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Verónica H López, Biology</last_name>
    <phone>986229900</phone>
    <phone_ext>+34</phone_ext>
    <email>vhernandez@rsstrials.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan A Gómez Hospital, MD, PhD</last_name>
      <phone>932 60 75 00</phone>
      <phone_ext>34</phone_ext>
      <email>jagomezh@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan F Muñoz, MD, PhD</last_name>
      <phone>937 36 50 50</phone>
      <phone_ext>34</phone_ext>
      <email>juanfranmc@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario General de Castellón</name>
      <address>
        <city>Castellón De La Plana</city>
        <state>Castellón</state>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cádiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Morales, MD, PhD</last_name>
      <phone>956 00 50 00</phone>
      <phone_ext>34</phone_ext>
      <email>fjose.morales.ssta@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Peral, MD, PhD</last_name>
      <phone>871 20 50 00</phone>
      <phone_ext>34</phone_ext>
      <email>vperal@ono.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Goicolea, MD, PhD</last_name>
      <phone>911 91 60 00</phone>
      <phone_ext>34</phone_ext>
      <email>j_goicolea@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Santa Lucía</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciano Consuegra, MD, PhD</last_name>
      <phone>968 12 86 00</phone>
      <phone_ext>34</phone_ext>
      <email>lconsue@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Pinar, MD, PhD</last_name>
      <phone>968 36 95 00</phone>
      <phone_ext>34</phone_ext>
      <email>epbhva@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres I Romo, MD, PhD</last_name>
      <phone>986811111</phone>
      <phone_ext>+34</phone_ext>
      <email>Andres.Iniguez.Romo@sergas.es</email>
    </contact>
    <contact_backup>
      <last_name>Víctor A Jiménez Díaz, MD, PhD</last_name>
      <phone>986811111</phone>
      <phone_ext>+34</phone_ext>
      <email>Victor.Alfonso.Jimenez.Diaz@sergas.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Baracaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koldobika G San Román, MD, PhD</last_name>
      <phone>946 00 60 00</phone>
      <phone_ext>+34</phone_ext>
      <email>KOLDOBIKA.GARCIASANROMAN@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manel Sabaté, MD, PhD</last_name>
      <phone>932 27 54 00</phone>
      <phone_ext>34</phone_ext>
      <email>masabate@clinic.ub.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio S Peñaranda, MD, PhD</last_name>
      <phone>932 91 90 00</phone>
      <phone_ext>+34</phone_ext>
      <email>aserrap@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Lozano, MD, PhD</last_name>
      <phone>926 27 80 00</phone>
      <phone_ext>34</phone_ext>
      <email>drlozano68@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastián Romaní, MD, PhD</last_name>
      <phone>927 256 200</phone>
      <email>sebastian.romani@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Germán Calle, MD, PhD</last_name>
      <phone>956 00 21 00</phone>
      <phone_ext>34</phone_ext>
      <email>gcallep@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doctor Josep Trueta</name>
      <address>
        <city>Gerona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymundo Ocaranza, MD, PhD</last_name>
      <phone>982 29 60 00</phone>
      <phone_ext>34</phone_ext>
      <email>raymundoocaranza@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Complejo Universitario Asistencial de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Áraba</name>
      <address>
        <city>Vitoria-Gasteiz</city>
        <state>Álava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spanish Society of Cardiology</investigator_affiliation>
    <investigator_full_name>Andres Iñiguez Romo, MD</investigator_full_name>
    <investigator_title>Head of cardiology</investigator_title>
  </responsible_party>
  <keyword>Magmaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

